Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs

Therapeutic Drug Monitoring

Volumn 36, Issue 1, 2014, Pages 125-130

  Kersten, Hege ^a,b   Wyller, Torgeir B ^a,c   Molden, Espen ^c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Hospital Pharmacies   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

adverse effects; anticholinergic activity; CYP2D6 CYP2C19; elderly patients; pharmacogenetics

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6;

AGED; ALLELE; ANTICHOLINERGIC EFFECT; ARTICLE; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; XEROSTOMIA;

AGE FACTORS; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CHOLINERGIC ANTAGONISTS; COGNITION; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; MUTATION; NORWAY; NURSING HOMES; PHARMACOGENETICS; PHENOTYPE; RADIOLIGAND ASSAY; STATISTICS, NONPARAMETRIC; XEROSTOMIA;

EID: 84892905156     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31829da990     Document Type: Article

References (41)

1. Tollefson GD, Montague-Clouse J, Lancaster SP, et al. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci. 1991;3:314-319.
2. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198-203.
3. Nebes RD, Pollock BG, Halligan EM, et al. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci. 2007;62:83-85.
4. Tune LE, Damlouji NF, Holland A, et al. Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet. 1981; 2:651-653.
5. Giron MS, Wang HX, Bernsten C, et al. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc. 2001;49:277-283.
6. Tamura BK, Bell CL, Inaba M, et al. Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med. 2012;28:217-236.
7. Haasum Y, Fastbom J, Johnell K. Institutionalization as a risk factor for inappropriate drug use in the elderly: a Swedish nationwide registerbased study. Ann Pharmacother. 2012;46:339-346.
8. Ray PG, Meador KJ, Loring DW, et al. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol. 1992;5:72-77.
9. Shah GN, Mooradian AD. Age-related changes in the blood-brain barrier. Exp Gerontol. 1997;32:501-519.
10. McLachlan AJ, Pont LG. Drug metabolism in older people-a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67:175-180.
11. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48:761-804.
12. Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
13. Yusuf I, Djojosubroto MW, Ikawati R, et al. Ethnic and geographical distributions of CYP2C19 alleles in the populations of Southeast Asia. Adv Exp Med Biol. 2003;531:37-46.
14. Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39:121-127.
15. Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003;31: 1255-1259.
16. Malhotra B, Darsey E, Crownover P, et al. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol. 2011;72: 226-234.
17. Kersten H, Molden E, Tolo IK, et al. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013;68:271-278.
18. Kersten H,Molden E,Willumsen T, et al. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J of Clin Pharmacol. 2013;75:842-849.
19. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56:1333-1341.
20. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: asso-ciations with serum anticholinergic activity. J Clin Pharmacol. 2006; 46:1481-1486.
21. Buntinx F, Niclaes L, Suetens C, et al. Evaluation of Charlson's comorbidity index in elderly living in nursing homes. J Clin Epidemiol. 2002; 55:1144-1147.
22. Marin DB, Flynn S,MareM, et al. Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale. Int J Geriatr Psychiatry. 2001;16:745-750.
23. Hendset MM, Molden EP, Refsum HMP, et al. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009;29:537-541.
24. Hendset M, Molden E, Knape M, et al. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit. 2014;36:80-85.
25. Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry. 1980;37:293-297.
26. Jakobsen SM, Kersten H, Molden E. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. J Am Geriatr Soc. 2011;59:501-505.
27. Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc. 2008;139(suppl):35S-40S.
28. Braekhus A, Laake K, Engedal K. The Mini-Mental State Examination: identifying the most efficient variables for detecting cognitive impairment in the elderly. J Am Geriatr Soc. 1992;40:1139-1145.
29. Fillenbaum GG, van BG, Morris JC, et al. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimer Demen. 2008;4:96-109.
30. Oishi M, Chiba K, Malhotra B, et al. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010;38:1456-1463.
31. Fox CR. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477-1483.
32. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508-513.
33. Waade RB, Molden E, Refsum H, et al. Serum concentrations of antidepressants in the elderly. Ther Drug Monit. 2012;34:25-30.
34. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry. 1987;44:418-426.
35. Wakeno M, Okugawa G, Takekita Y, et al. Delirium associated with paroxetine in an elderly depressive patient: a case report. Pharmacopsychiatry. 2007;40:199-200.
36. Stephan PL, Jaquenoud SE, Mueller B, et al. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry. 2006;39:150-152.
37. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-121.
38. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
39. Flacker JM, Wei JY. Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci. 2001;56:M353-M355.
40. Flacker JM, Lipsitz LA. Serum anticholinergic activity changes with acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci. 1999;54:M12-M16.
41. Carnahan RM, Lund BC, Perry PJ, et al. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol Bull. 2002;36:24-39.